Imunon Says $15.7M In Cash, Investments, And Accrued Interest Receivable And Future Planned Sales Of The Company's Remaining $1.3M Of New Jersey NOLS, Is Expected to Provide Cash Runway Into Q4 2024
Imunon Says $15.7M In Cash, Investments, And Accrued Interest Receivable And Future Planned Sales Of The Company's Remaining $1.3M Of New Jersey NOLS, Is Expected to Provide Cash Runway Into Q4 2024
Imunon表示，1570萬美元的現金、投資和應計應收利息以及該公司剩餘的130萬美元新澤西州NOLS的未來計劃銷售將爲2024年第四季度提供現金流
Imunon Says $15.7M In Cash, Investments, And Accrued Interest Receivable And Future Planned Sales Of The Company's Remaining $1.3M Of New Jersey NOLS, Is Expected to Provide Cash Runway Into Q4 2024
Imunon表示，1570萬美元的現金、投資和應計應收利息以及該公司剩餘的130萬美元新澤西州NOLS的未來計劃銷售將爲2024年第四季度提供現金流
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。